Ophthalmology Times

Ophthalmology Times Cutting-Edge Advancements
Twitter.com/OphthTimes Posting Policy:
Thank you for liking the official Ophthalmology Times page. We're glad you're here.

We are committed to creating a community that encourages self-expression and mirrors the values of Ophthalmology Times including respect for the rights, dignity, and property of others. We ask all fans to do their part to help us achieve the goal. In doing that, we ask you not to post content that:
-is threatening, abusive, obscene, indecent, or objectionable.
-is deceptive, false, or misleading
-

violates the intellectual property rights of other people
-is illegal
-references a third party website or is self-promoting spam
-is inappropriate, offensive, or hateful
We reserve the right to remove any content or block users that violate our community guidelines, or that we determine are otherwise offensive to our community. All content must also comply with Facebook's policies as well.

Rising Star: Introducing Adam Jacobson, MD—Michigan pediatric ophthalmologist advances childhood glaucoma care with long...
05/27/2026

Rising Star: Introducing Adam Jacobson, MD—Michigan pediatric ophthalmologist advances childhood glaucoma care with longer-lasting Ahmed valves, Ologen, and new clues on prematurity glaucoma.

Michigan pediatric ophthalmologist advances childhood glaucoma care with longer-lasting Ahmed valves, Ologen, and new clues on prematurity glaucoma.

Subclinical differences in corneal nerve architecture, mechanosensitivity, and immune cell morphodynamics persist in eye...
05/26/2026

Subclinical differences in corneal nerve architecture, mechanosensitivity, and immune cell morphodynamics persist in eyes that have undergone myopic LASIK surgery up to two years prior, according to a prospective observational study published in The Ocular Surface.

Two years after LASIK, hidden corneal nerve loss and immune activation persist, with higher IL‑16 and faster T‑cell motion despite normal exams.

Deborah Ristvedt, DO, who is in practice with Vance Thompson Vision in Alexandria, Minnesota, moderated an Ophthalmology...
05/25/2026

Deborah Ristvedt, DO, who is in practice with Vance Thompson Vision in Alexandria, Minnesota, moderated an Ophthalmology Times Case-Based Roundtable® at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting in Washington, DC, and focused on interventional approaches in glaucoma management. The discussion emphasized a paradigm shift toward earlier, proactive strategies to reduce medication burden, improve IOP stability, and preserve visual function across mild-to-severe disease.

Three cases illustrate how earlier, proactive intervention can reduce medication burden and preserve vision across a range of glaucoma severity.

A study published in the British Journal of Ophthalmology found that patients who experience transient visual loss (TVL)...
05/24/2026

A study published in the British Journal of Ophthalmology found that patients who experience transient visual loss (TVL) have an increased risk of short- and long-term major adverse cardiovascular events, stroke, myocardial infarction, arrhythmia, and hospitalization, warranting prompt systemic evaluation and long-term monitoring, according to the authors led by Tasha Miller, MD, from the Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. She was joined in this study by colleagues from the Department of Ophthalmology and Vision Sciences and the Division of Neurology, Department of Medicine, both in the University of Toronto.

Transient vision loss may foreshadow stroke or heart events; study urges urgent 90-day evaluation and long-term cardiovascular monitoring.

Investigators reported the case of a 61-year-old woman, a musician who played the oboe, who presented with the complaint...
05/23/2026

Investigators reported the case of a 61-year-old woman, a musician who played the oboe, who presented with the complaint of eye squinting, ie, benign essential blepharospasm, that was described as progressive and involuntary and had been present over a period of 4 years.

The patient was initially diagnosed with dry eye, but the symptoms did not respond to instillation of artificial tears. She did not have a history of use of dopamine receptor antagonists. A noteworthy observation was that “her symptoms reliably abated when she played the oboe or when she sang, only to return immediately after stopping.”

Investigators noted the patient's symptoms "reliably abated when she played the oboe or when she sang, only to return immediately after stopping.”

Sunil S. Patel, MD, PhD, of the University of Texas Southwestern Medical Center, breaks down QA102's first-in-class mech...
05/22/2026

Sunil S. Patel, MD, PhD, of the University of Texas Southwestern Medical Center, breaks down QA102's first-in-class mechanism targeting harmful gut bacteria and retinal inflammation, what the phase 2 drusen volume and GA growth rate data reveal about the therapy's potential, and what a phase 3 program must address to bring an oral AMD treatment to patients who currently have no options.

Sunil S. Patel, MD, PhD, of the University of Texas Southwestern Medical Center, breaks down QA102's first-in-class mechanism targeting harmful gut bacteria and retinal inflammation, what the phase 2 drusen volume and GA growth rate data reveal about the therapy's potential, and what a phase 3 progr...

Swissmedic, the Swiss Agency for Therapeutic Products, has granted orphan drug status (ODS) to tinlarebant (Belite Bio) ...
05/21/2026

Swissmedic, the Swiss Agency for Therapeutic Products, has granted orphan drug status (ODS) to tinlarebant (Belite Bio) for the treatment of Stargardt disease type 1 (STGD1), an inherited macular dystrophy for which no approved pharmacologic therapy currently exists anywhere in the world.

The designation follows positive topline results from the pivotal phase 3 DRAGON trial reported in December 2025 and adds Switzerland to a growing list of jurisdictions—including the United States, the European Union, and Japan—in which tinlarebant has received expedited or orphan-tier recognition.

Swiss regulator backs tinlarebant for Stargardt as DRAGON phase 3 shows slower retinal atrophy, bringing first treatment closer to patients.

A documented gap exists in neuro-ophthalmology training: residents in both neurology and ophthalmology programs report v...
05/21/2026

A documented gap exists in neuro-ophthalmology training: residents in both neurology and ophthalmology programs report variable exposure and lower confidence when evaluating neuro-ophthalmic cases, often depending on faculty availability and institutional resources.

EyeSpy Consults is an app developed by a neuro-ophthalmology fellow, a cloud engineer, and faculty at Beth Israel Deaconess Medical Center to explore whether a structured digital tool can help address this. The app organizes consult guidance around three entry points — symptoms, suspected diagnoses, and exam findings — and walks trainees through decision trees that include testing recommendations and criteria for urgent subspecialty referral.

A pilot study with neurology and ophthalmology residents is measuring changes in self-reported confidence and ability to describe a structured approach to common consults before and after use.

The app is designed to improve confidence among neurology and ophthalmology trainees.

Biogen Inc. announced it has completed its acquisition of Apellis Pharmaceuticals Inc., making Apellis a wholly owned su...
05/20/2026

Biogen Inc. announced it has completed its acquisition of Apellis Pharmaceuticals Inc., making Apellis a wholly owned subsidiary and absorbing SYFOVRE into what is now an expanded immunology and complement-focused commercial portfolio

Biogen buys Apellis, taking over Syfovre for geographic atrophy—what it means for GA care, trial data, safety signals, and future formulations.

Turkish researchers reported significant positive changes in ocular transparency in the lens, cornea, and anterior segme...
05/19/2026

Turkish researchers reported significant positive changes in ocular transparency in the lens, cornea, and anterior segment in patients who underwent laparoscopic sleeve gastrectomy.

Obesity, they explained, can significantly affect ocular health, specifically the corneal epithelium and corneal sensitivity. In addition, changes in the corneal hysteresis, corneal resistance factor, and intraocular pressure (IOP) in obese patients may indicate the risk of development of glaucoma. Other changes resulting from obesity include small nerve fiber damage and inflammation in corneal tissue, and there is an increased risk of age-related, cortical, and posterior subcapsular cataracts.

New Turkish study links sleeve gastrectomy weight loss to clearer cornea and lens, lower eye pressure, and widened anterior chamber in 6 months.

A Danish study, published in JAMA Dermatology, found that topical and systemic corticosteroids used in the short term do...
05/18/2026

A Danish study, published in JAMA Dermatology, found that topical and systemic corticosteroids used in the short term do not result in increased intraocular pressure (IOP) in adults with or without atopic dermatitis.

Danish JAMA Dermatology trials show short-term topical or oral corticosteroids don’t raise intraocular pressure, easing glaucoma worries in atopic dermatitis care.

Address

25115 Country Club Boulevard
North Olmsted, OH
44070

Telephone

(440) 243-8100

Website

Alerts

Be the first to know and let us send you an email when Ophthalmology Times posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Ophthalmology Times:

Shortcuts

Share

Category